# Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis

> **NCT03174587** · PHASE1 · COMPLETED · sponsor: **Corestemchemon, Inc.** · enrollment: 7 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **BIOLOGICAL:** allogenic bone marrow derived mesenchymal stem cells

## Key facts

- **NCT ID:** NCT03174587
- **Lead sponsor:** Corestemchemon, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-30
- **Primary completion:** 2019-03-12
- **Final completion:** 2019-08-19
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2019-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03174587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03174587, "Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03174587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*